FDA Delays: Nicotine Pouch Authorisation Hinges on Youth Risk Concerns

The Food and Drug Administration (FDA) is holding off on authorising several popular nicotine pouch products in the U.S. A fast-track scheme designed to accelerate approvals has been stalled due to concerns over potential risks to new users, including children, according to three anonymous sources within the agency.

Newer tobacco alternatives like nicotine pouches, which are placed under the lip for a buzz, require FDA approval to be legally sold in the world's largest smoking alternatives market, valued at approximately $22 billion. Concerns over the safety of these products are impacting tobacco giants such as Philip Morris International and British American Tobacco.

Despite a pilot programme aimed at speeding up applications for these products, the FDA remains cautious. The agency is weighing the potential benefits of encouraging smokers to switch against the risks of increased use among non-smokers and youth, as shown by rising popularity in recent surveys.